| Hepatitis C, Chronic
Alvaiz vs Epclusa
Side-by-side clinical, coverage, and cost comparison for hepatitis c, chronic.Deep comparison between: Alvaiz vs Epclusa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEpclusa has a higher rate of injection site reactions vs Alvaiz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Epclusa but not Alvaiz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alvaiz
Epclusa
At A Glance
Oral
Daily
TPO-receptor agonist
Oral
Once daily
NS5B polymerase and NS5A inhibitor
Indications
- Immune thrombocytopenic purpura
- Hepatitis C, Chronic
- Severe Aplastic Anemia
- Hepatitis C, Chronic
Dosing
Immune thrombocytopenic purpura Initiate at 36 mg orally once daily (18 mg for East-/Southeast-Asian ancestry or hepatic impairment; 9 mg for both); adjust in 18-mg increments to maintain platelet count >=50 x 10^9/L; maximum 54 mg daily.
Hepatitis C, Chronic Initiate at 18 mg orally once daily; adjust in 18-mg increments every 2 weeks to achieve platelet count needed to initiate or maintain pegylated interferon and ribavirin therapy; maximum 72 mg daily; discontinue when antiviral therapy is discontinued.
Severe Aplastic Anemia Initiate at 36 mg orally once daily (18 mg for East-/Southeast-Asian ancestry or hepatic impairment); adjust in 36-mg increments every 2 weeks to maintain platelet count >=50 x 10^9/L; maximum 108 mg daily.
Chronic Hepatitis C (genotypes 1-6, without cirrhosis or compensated cirrhosis) One 400 mg/100 mg tablet orally once daily for 12 weeks (adults); weight-based dosing for pediatric patients 3 years and older (150 mg/37.5 mg for <17 kg, 200 mg/50 mg for 17-<30 kg, 400 mg/100 mg for >=30 kg) once daily for 12 weeks.
Chronic Hepatitis C (genotypes 1-6, with decompensated cirrhosis Child-Pugh B or C) One 400 mg/100 mg tablet orally once daily plus weight-based ribavirin (1,000 mg/day if <75 kg, 1,200 mg/day if >=75 kg, divided twice daily) for 12 weeks.
HCV/HIV-1 coinfection Follow dosing recommendations as above based on cirrhosis status.
Liver transplant recipients (without cirrhosis or compensated cirrhosis) One 400 mg/100 mg tablet orally once daily for 12 weeks.
Contraindications
—
- Contraindications applicable to ribavirin when used in combination with EPCLUSA (refer to ribavirin prescribing information)
Adverse Reactions
Most common (>=3%) Nausea, diarrhea, upper respiratory tract infection, vomiting, urinary tract infection, increased ALT, myalgia, oropharyngeal pain, increased AST, pharyngitis, back pain, influenza, paresthesia, rash
Serious Hemorrhage, thrombotic/thromboembolic complications, hepatic decompensation, hepatotoxicity, cataracts
Postmarketing Skin discoloration including hyperpigmentation and skin yellowing
Most common (>=10%) in subjects without cirrhosis or compensated cirrhosis Headache, fatigue
Most common (>=10%) in subjects with decompensated cirrhosis (with ribavirin) Fatigue, anemia, nausea, headache, insomnia, diarrhea
Most common (>=10%) in HCV/HIV-1 coinfected subjects Fatigue, headache
Additional reactions (5-<10%) in subjects without cirrhosis or compensated cirrhosis Nausea, asthenia, insomnia, irritability
Less common (<5%) in subjects without cirrhosis or compensated cirrhosis Rash, depressed mood
Less common (<10%) in subjects with decompensated cirrhosis Rash
Serious Serious symptomatic bradycardia when coadministered with amiodarone
Postmarketing Serious symptomatic bradycardia with sofosbuvir-containing regimens and amiodarone, skin rashes with blisters or angioedema-like swelling, angioedema
Pharmacology
Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (cMpl), initiating signaling cascades that induce proliferation and differentiation of megakaryocytes, leading to increased platelet production.
Sofosbuvir is a nucleotide prodrug that inhibits HCV NS5B RNA-dependent RNA polymerase by incorporating into viral RNA and acting as a chain terminator. Velpatasvir inhibits the HCV NS5A protein required for viral replication.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alvaiz
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (1/12)
Epclusa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (1/12) · Qty limit (11/12)
UnitedHealthcare
Alvaiz
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Epclusa
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Alvaiz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Epclusa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availablePAF Co-Pay Relief: Aplastic Anemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Epclusa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlvaizView full Alvaiz profile
EpclusaView full Epclusa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.